Accentuate the Positive: Tackling Pharma’s Reputation Problem

|

article image
“Merck’s Head Defends Drug Prices,” ran The New York Times headline. The Times was reporting on the Merck & Co. president’s testimony at the previous day’s Senate hearing, part of a high-profile investigation into the price-setting activities of the US pharmaceutical industry. Merck’s leader offered a robust defense, stressing that the industry was highly competitive and that it was actually giving the American public “a reasonable bargain.” But The Timesreporter noted that the testimony was an indication “of the drug industry’s realization that its reputation was on trial.”

Spotlight

Rare Disease Report

Rare Disease Report provides an independent voice to the rare disease community. Through our multi-channel distribution platform, we provide our audience of clinicians, advocates, patients, scientists, and pharma professionals, the up-to-date information relevant to the rare disease community.

OTHER ARTICLES

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

Pricing of drugs – at what cost?

Article | April 10, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

What are the advantages of PCD Pharma Company?

Article | April 10, 2020

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | April 10, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

Spotlight

Rare Disease Report

Rare Disease Report provides an independent voice to the rare disease community. Through our multi-channel distribution platform, we provide our audience of clinicians, advocates, patients, scientists, and pharma professionals, the up-to-date information relevant to the rare disease community.

Events